PT  - JOURNAL ARTICLE
AU  - Hoyle, Brian
ED  - Powell, Jerry S.
ED  - Tiede, Andreas
ED  - Sokal, Etienne
TI  - Advances and Potential in Treatment of Hemophilia A
DP  - 2015 Sep 10
TA  - MD Conference Express
PG  - 12--13
VI  - 15
IP  - 21
4099  - http://mdc.sagepub.com/content/15/21/12.short
4100  - http://mdc.sagepub.com/content/15/21/12.full
AB  - Treatment of hemophilia A is benefiting from extended half-life recombinant factor VIII compounds that maintain higher trough levels of drug with less frequent dosing. A variety of pegylated recombinant factor VIII compounds are available. A promising avenue of treatment is the targeted use of liver mesenchymal stem cells that produce factor VIII.